Approved Hospital Formulary
Add Formweb to your mobile device
Approved Hospital Formulary
Search results for:
leuprolide
leuprolide
- Formulary Miscellaneous Program Formulary
- Restricted Use in outpatient setting or indications listed below
- Restricted Miscellaneous
| Drug Name | Form | Strength | Formulary Unrestricted | Formulary Restricted | Non-Formulary | Interchange |
|---|---|---|---|---|---|---|
| Leuprolide Acetate | INJECTION, SUBCUTANEOUS | 14 mg/2.8 mL vial | ||||
| Eligard | KIT, SUBCUTANEOUS | 7.5 mg/month | ||||
| Eligard | KIT, SUBCUTANEOUS | 22.5 mg/3 month, 30 mg/4 month, 45 mg/6 month | ||||
| Lupron Depot | POWDER FOR INJECTION, EXTENDED RELEASE, INTRAMUSCULAR | 3.75 mg/month | ||||
| Lupron Depot | POWDER FOR INJECTION, EXTENDED RELEASE, INTRAMUSCULAR | 7.5 mg/month, 11.25 mg/3 months, 22.5 mg/3 months | ||||
| Lupron Depot-Ped | POWDER FOR INJECTION, EXTENDED RELEASE, INTRAMUSCULAR | 7.5 mg/month | ||||
| Lupron Depot-Ped | POWDER FOR INJECTION, EXTENDED RELEASE, INTRAMUSCULAR | 15 mg/month, 11.25 mg/3 months, 30 mg/3 months | ||||
| Lupron Depot | POWDER FOR INJECTION, EXTENDED RELEASE, INTRAMUSCULAR | 30 mg/4 months |
Last updated: Oct. 4, 2023
- HAZ-MED: Group 1
- Hormonal Therapy: This drug is a hormonal therapy in used in oncologic conditions. This drug may be resumed by a hospitalist or non-oncology healthcare provider without contacting an oncology pharmacy specialist or consulting an oncologist.
Lupron Injection medication guide
Lupron Depot-Ped medication guide
Inpatient Use: Attempt to defer orders to outpatient as possible. If use is required, the 3.75 mg (Lupron) and 7.5 mg (Eligard, Lupron-Ped) monthly injections will be dispensed.
Prostate Cancer:
Interchange Lupron Depot with Eligard at a 1 mg : 1 mg ratio in prostate cancer patients (outpatients).
If leuprolide acetate is ordered for inpatients the pharmacist should contact the prescriber to determine if the dose can be deferred until after discharge. If the dose cannot be deferred, then the Eligard 7.5 mg dose providing one month of drug should be given for prostate cancer patients.
Uterine eiomyomas, precocious puberty and endometriosis:
Lupron will remain the formulary agent for uterine leiomyomas, precocious puberty and endometriosis.
If leuprolide acetate is ordered for inpatients the pharmacist should contact the prescriber to determine if the dose can be deferred until after discharge. For endometriosis or uterine leiomyomas, for inpatient use if the dose cannot be deferred to outpatient setting, the Lupron Depot 3.75 mg should be given. The appropriate weight based monthly dosage may be provided for precocious puberty.
All other indications, uses, and dosage forms are restricted to the outpatient setting.
Leuprolide acetate 14 mg/2.8 mL MDV: restricted for use in endocrinology clinic.
Reviewed: April 24, 2007 (Lupron Depot), and 24 April 2018, and August 2022 (leuprolide acetate)